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Single Center Study of the Impella Pump 
Supraja Thunuguntla, Charles F. Mild 
Department of Internal Medicine at The University of Texas Rio Grande Valley, Valley Baptist Medical 
Center 
 
Background 
 Impella® is a percutaneously inserted ventricular assist device. Its use increased from 11 
devices placed in 2016 to 39 in 2019 at Valley Baptist Medical Center (VBMC). We review the 
anticoagulation options, side effects and mortality. 
 
Methods 
We conduct a retrospective chart review of all patients placed on Impella from January 1, 2016 
to March 31, 2020 admitted to VBMC. A final sample of 107 patients was collected. Descriptive 
statistics were used to assess the distribution of variables; continuous variables summarized as 
mean values with standard deviations and categorical variables summarized as counts and 
percentages.  
 
Results 
The indication for Impella was protected percutaneous coronary intervention (PCI) (71%, of 
which 18.4% was intervention on a previous coronary artery bypass graft, CABG), cardiogenic 
shock (17.7%) or coronary angiogram prior to CABG (11.3%). Average duration of being placed 
on support was 1.3±1.8 days. 
Periprocedural anticoagulants administered by cardiologist were heparin (H), bivalirudin (B), or 
both. Some patients received enoxaparin (E) [dosed as per ACS protocol] for ≥24hrs before the 
procedure.  Anticoagulation groups are H (55.1%), B (22.4%), H+B (7.5%), E+H (3.7%), E+B 
(8.4%), and none (2.8%). Observed side effects were acute bleeding (18.7%) with hemoglobin 
≤7 mg/dl by group is 10.1% vs 20.8% vs 37.5% vs 50% vs 33.3 respectively (p=0.06), femoral 
pseudoaneurysm (2.8%) and retroperitoneal bleed (0.9%). Average aPTT was 70-140 seconds 
in the heparin group, ACT (measured in 9.3% of patients only) was 275±212.4, fibrinogen 
(measured in 12.1% of patients only) was 356±125.8. 
Death within a month (32/107) occurred when indication was cardiogenic shock (83.3%) versus 
protected PCI (28.9%) (p=0.00018). 
 
Conclusion 
In agreeance with the manufacturer's recommendation, the lowest risk of bleeding is observed 
with heparin (dosing: weight-based) only. Further clinical studies required for having a 
standardized protocol for anticoagulation with dosing and duration of therapy. 
 
  
 
 
 
 
 
 
 
 
 
 
 
